Biohaven had its Relative Strength (RS) Rating upgraded from 65 to 76 Thursday — a welcome improvement, but still below the 80 or better score you prefer to see.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Decades of market research shows that the best-performing stocks tend to have an 80 or better RS Rating in the early stages of their moves. See if Biohaven can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Biohaven is building a consolidation with a 55.70 entry. See if it can clear the breakout price in heavy volume.
The company reported 0% earnings growth in its most recent report, while sales growth came in at 0%.
Biohaven holds the No. 228 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
